Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Cash & Equivalents (2016 - 2026)

Pharma-Bio Serv filings provide 17 years of Cash & Equivalents readings, the most recent being $5.8 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 21.12% to $5.8 million in Q1 2026 year-over-year; TTM through Jan 2026 was $5.8 million, a 21.12% decrease, with the full-year FY2025 number at $3.4 million, down 50.07% from a year prior.
  • Cash & Equivalents hit $5.8 million in Q1 2026 for Pharma-Bio Serv, up from $3.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $15.4 million in Q1 2022 to a low of $2.1 million in Q2 2025.
  • Median Cash & Equivalents over the past 5 years was $6.8 million (2024), compared with a mean of $7.7 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 79.85% in 2023 and later skyrocketed 127.22% in 2024.
  • Pharma-Bio Serv's Cash & Equivalents stood at $14.5 million in 2022, then fell by 27.77% to $10.4 million in 2023, then plummeted by 35.22% to $6.8 million in 2024, then tumbled by 50.07% to $3.4 million in 2025, then soared by 70.56% to $5.8 million in 2026.
  • The last three reported values for Cash & Equivalents were $5.8 million (Q1 2026), $3.4 million (Q4 2025), and $4.0 million (Q3 2025) per Business Quant data.